Goodrx Holdings, INC

GoodRx Holdings, Inc. reported the final voting results from its Annual Meeting of Stockholders held on June 16, 2026, confirming the election of directors, ratification of auditors, and approval of executive compensation.

GoodRx Holdings, Inc. has promoted Thomas Chan to the role of Chief Accounting Officer, effective immediately.

GoodRx Holdings announces the resignation of Director Ian T. Clark and a subsequent board rebalancing involving CEO Wendy Barnes.

GoodRx Holdings, Inc. announced the resignation of its Chief Accounting Officer, Romin Nabiey, effective April 3, 2026, as he pursues other opportunities.

GoodRx Holdings, Inc. announced its Board of Directors approved a $72,918 discretionary cash bonus for Chief Accounting Officer Romin Nabiey for 2025 performance.

GoodRx Holdings, Inc. announced the resignation of Dipanjan Deb from its Board of Directors, effective February 26, 2026.

GoodRx Holdings reports a decrease in revenue and net income for Q1 2026, impacted by retail pharmacy landscape changes and a shift towards Pharma Direct offerings.

GoodRx reported a slight revenue increase but a significant net income drop in Q3 2025, as growth in pharma solutions was offset by declines in prescription transactions and active consumers amid retail pharmacy landscape changes.

GoodRx reports increased net income and Adjusted EBITDA in Q2 2025, despite declines in prescription transactions and subscription revenue due to retail pharmacy landscape changes.

GoodRx Holdings, Inc. reports a 3% increase in revenue and a return to net income profitability for the first quarter of 2025, navigating changes in the retail pharmacy sector.

GoodRx Holdings saw an 8% increase in revenue and a significant improvement in profitability in the third quarter of 2024, compared to the same period last year.

GoodRx Holdings, Inc. announced a 6% increase in revenue for the second quarter of 2024, alongside a decrease in net income compared to the same period last year, while navigating a changing retail pharmacy environment.

GoodRx Holdings, Inc. reported a 1% revenue increase in 2025, driven by strong pharma direct growth despite challenges in prescription transactions and a changing retail pharmacy landscape.

GoodRx Holdings, Inc. reports a 6% increase in revenue for 2024, driven by growth in prescription transactions and pharma manufacturer solutions, while navigating a changing retail pharmacy landscape.

GoodRx Holdings details its dual-class stock structure, board composition, and anti-takeover provisions in a recent SEC filing.

Christopher A Mcginnis, See Remarks of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.

Wendy Lynn Barnes, See Remarks and a Director of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.

Thomas (Tc) Chan, Chief Accounting Officer of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.

Director Agnes Rey-Giraud was granted 73,434 restricted stock units in GoodRx Holdings, Inc.

GoodRx Holdings, Inc. director Kelly J. Kennedy was granted 73,434 restricted stock units as part of standard equity compensation.

Director Douglas Hirsch was granted 73,434 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.

GoodRx Holdings, Inc. has filed a definitive proxy statement with the SEC regarding its FY24 activities.

GoodRx Holdings will hold its annual stockholders meeting virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

GoodRx Holdings, Inc. has appointed Simon Patterson to its Board of Directors, effective immediately, following the resignation of Adam Karol in March 2024.

GoodRx Holdings, Inc. has filed a definitive proxy statement with the SEC regarding its FY23 activities.

GoodRx Holdings will hold its annual stockholders meeting virtually on June 6, 2024, to vote on director elections, auditor ratification, and executive compensation.

Spectrum Equity entities have fully divested their beneficial ownership in GoodRx Holdings, Inc. through a pro rata distribution and subsequent open market sales.

Spectrum Equity entities have reduced their beneficial ownership in GoodRx Holdings, Inc. to 8.28% following a pro rata distribution and subsequent open market sales.

Spectrum Equity has amended its Schedule 13D filing for GoodRx Holdings, Inc., disclosing a pro rata distribution of Class A Common Stock to its limited partners and subsequent open market sales, reducing its beneficial ownership to 12.9%.

Spectrum Equity, a significant shareholder in GoodRx Holdings, Inc., has reduced its beneficial ownership to 15.9% of Class A Common Stock after distributing over 3.9 million shares to limited partners and conducting open market sales.

GoodRx Holdings, Inc. has completed the previously announced repurchase of 7 million shares of Class A Common Stock from Idea Men, LLC for $4.20 per share, reducing Idea Men's beneficial ownership to 29.1%.

GoodRx Holdings, Inc. has entered into an agreement to repurchase 7 million shares of its Class A Common Stock from Idea Men, LLC for $29.4 million, reducing the major shareholder's stake.

The Vanguard Group has reported 0% beneficial ownership in GoodRx Holdings Inc. following an internal realignment.

The Vanguard Group has reported an increased beneficial ownership of 9.33% in GoodRx Holdings Inc, holding over 9.2 million shares.

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have reported reducing their beneficial ownership in GoodRx Holdings, Inc. Class A Common Stock to 4.3% as of March 31, 2025.

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, indicating they no longer hold a reportable beneficial ownership stake in GoodRx Holdings, Inc. as of March 31, 2025.

Rubric Capital Management LP and David Rosen have disclosed a passive beneficial ownership of 5.57% in GoodRx Holdings, Inc.'s Class A Common Stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander jointly report beneficial ownership of 2,186,869 shares of GoodRx Holdings, Inc., representing 2.1% of the company's Class A Common Stock.